TRVI PRESS-RELEASE SEC Filing Analysis

Final — all horizons settled through T+60d

TRVI ▲ +12.65% at T+60d

NEUTRAL call ✓ call won +12.65% · α vs SPY +1.12% · entry $11.94 → $13.45

Last close $13.50 (close Jun 8) · +13.07% from $11.94 entry

Entry anchored
Mar 10, 03:59 PM ET
via Databento tick

T+1d

-6.20%

call -6.20% · α -4.71%

$11.20

settled 3mo ago

T+5d

-10.47%

call -10.47% · α -8.28%

$10.69

settled 3mo ago

T+20d

+11.39%

call +11.39% · α +10.87%

$13.30

settled 2mo ago

T+60d

+12.65%

call +12.65% · α +1.12%

$13.45

settled 6d ago

Price Chart

Loading chart...

Executive Summary

Trevi Therapeutics announced an upcoming conference call to discuss its fourth quarter and full-year 2025 financial results, along with business updates. No financial data was released in this press release, which serves only as a notification of the forthcoming earnings event.

Actionable Insight

Traders should monitor the upcoming earnings call on March 17 for potential updates on clinical progress, cash runway, or guidance that could impact valuation, particularly given the lack of approved therapies in the target indications.

Key Facts

Trevi Therapeutics will host a conference call on March 17, 2026, at 4:30 p.m. ET to discuss Q4 and full-year 2025 financial results.
The call will include senior management and will be webcast live; registration is required.
No financial results or material business updates were disclosed in this release.
The company is developing Haduvio™ (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and refractory chronic cough (RCC).
Haduvio has shown statistically significant reduction in cough frequency in clinical trials but is not yet approved by the FDA.

Financial Impact

No financial data disclosed in this release

Risk Factors

No financial or operational results are available in this release, limiting immediate trading relevance.
As a clinical-stage biopharma with no approved products, TRVI remains highly dependent on clinical trial outcomes and regulatory decisions.

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3253310

8 reports for TRVI

T+1T+5T+20T+60

100% Hit rate 3 of 3 directional calls best @ T+60▲ +15.38%Mar 9, 2026

Filters

Reports for TRVI — sortable, filterable
	Type				Now
Apr 21, 2026 7w ago	DEFA14A NEUTRAL ★ 3/10	$14.80 $13.24	▼ −10.54%	▼ −13.71%	$13.50 (−8.78%)
Apr 20, 2026 7w ago	Press Release NEUTRAL ★ 5/10	$14.62 $13.43	▼ −8.14%	▼ −13.05%	$13.50 (−7.66%)
Apr 17, 2026 7w ago	424B5 BEARISH ★ 7/10	$15.40 $13.43	▲ +12.79%	▲ +16.99%	$13.50 (+12.34%)
Apr 17, 2026 7w ago	8-K BEARISH ★ 7/10	$15.23 $15.08	▲ +0.98%	▲ +6.36%	$13.50 (+11.36%)
Apr 17, 2026 7w ago	Press Release NEUTRAL ★ 6/10	$15.23 $15.08	▼ −0.98%	▼ −6.36%	$13.50 (−11.36%)
Mar 17, 2026 12w ago	Press Release MIXED ★ 6/10	$10.69 $14.54	▲ +36.02%	▲ +29.97%	$13.50 (+26.29%)
Mar 10, 2026 13w ago	Press Release NEUTRAL ★ 3/10	$11.94 $13.30	▲ +11.39%	▲ +10.87%	$13.50 (+13.07%)
Mar 9, 2026 13w ago	Press Release BULLISH ★ 7/10	$11.70 $13.10	▲ +11.97%	▲ +14.77%	$13.50 (+15.38%)

US Market Status

Market Closed — Opens in 7h 20m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access